كتاب
Cervical cancer
- References
1. https://www.nccn.org/guidelines/category_1
3. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines
4. Ronco G, Dillner J, Elfstro¨m KM et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524–532.
5. Yoneda JY, Braganca JF, Sarian LO et al. Surgical treatment of microinvasive cervical cancer: analysis of pathologic features with implications on radicality. Int J Gynecol Cancer 2015; 25: 694–698.
6. Wagenaar HC, Trimos JB, Postema S et al. Tumor diameter and volume assessed by magnetic resonance imaging in the prediction of outcome for invasive cervical cancer. Gynecol Oncol 2001; 82: 474–482.
7. Patel CN, Nazir SA, Khan Z et al. 18F-FDG PET/CT of cervical carcin- oma. AJR Am J Roentgenol 2011; 196: 1225–1233.
8. Dittrich R, Lotz L, Hackl J et al. Fertilit€atserhalt bei Krebserkrankungen. Frauenarzt 2014; 55: 240–246.
9. Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjólfsdóttir B, Kim JW, Gleeson N, Brotto L, Tu D, Shepherd LE; CX.5 SHAPE investigators; CX.5 SHAPE Investigators, Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer, N Engl J Med. 2024 Feb 29;390(9):819-829
10. Diab Y. Sentinel lymph nodes mapping in cervical cancer a comprehensive review. Int J Gynecol Cancer 2017; 27: 154–158.
11. Kim SM, Choi HS, Byun JS. Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. Int J Gynecol Cancer 2000; 10: 305–312.
12. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 2003; 39: 2470–2486.
13. Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2012; 12: CD007406.
14. CORRIGENDUM, Cervical cancer: ESMO Clinical Practice Guidelines for C. Marth, F. Landoni, S. Mahner, M. McCormack, A. Gonzalez-Martin & N. Colombo, on behalf of the ESMO Guidelines Committee, diagnosis, treatment and follow-up, Annals of Oncology 29 (Supplement 4): iv262, 2018.
15. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73:177-183.
16. Rotman M, Sedlis A, Piedmonte MR, et al. A phase Ill randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169-176.
17. Peters W.A., III, Liu P.Y., Barrett R.J., II, Stock R.J., Monk B.J., Berek J.S., Souhami L., Grigsby P., Gordon W., Jr., Alberts D.S. Concurrent Chemotherapy and Pelvic Radiation Therapy Compared with Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix. Clin Oncol. 2000;18:1606–1613.
18. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus
cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative paraaortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 1339–1348.
19. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and
chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144–1153.
20. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with
pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137–
1143.
21.Keys HM, Bundy BN, Stehman FB et al. Cisplatin, radiation, and adjuvant hysterectomy
compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N
Engl J Med 1999; 340: 1154–1161.
22.Peters WA, 3rd, Liu PY, Barrett RJ, 2nd et al. Concurrent chemotherapy and pelvic radiation
therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery
in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606–1613.
23.Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties
about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-
analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008; 26: 5802–
5812.
24. Eun Ji Nam, Maria Lee, Ga Won Yim, Jae Hoon Kim, Sunghoon Kim, Sang Wun Kim, Jae
Wook Kim, Young Tae Kim, Comparison of Carboplatin‐ and Cisplatin‐Based Concurrent
Chemoradiotherapy in Locally Advanced Cervical Cancer Patients With Morbidity Risks
The Oncologist, Volume 18, Issue 7, July 2013, Pages 843–849,
25. Cetina, Lucely Rivera, Lesbia, Candelaria, Myrna de la Garza, Jaim, Dueñas-González,
Alfonso, Chemoradiation with gemcitabine for cervical cancer in patients with renal failure
Anti-Cancer Drugs 15(8):p 761-766, September 2004.
26.Moore DH, Blessing JA, McQuellon RP et al. Phase III study of cisplatin with or without
paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a
Gynecologic Oncology Group Study.J Clin Oncol 2004; 22: 3113–3119.
27.Long HJ 3rd, Bundy BN, Grendys EC Jr et al. Randomized phase III trial of cisplatin with or
without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J
Clin Oncol 2005; 23:4626–4633.
28.Monk BJ, Sill MW, Burger RA et al. Phase II trial of bevacizumab in the treatment of
persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group
study. J Clin Oncol 2009; 27: 1069–1074.
29.Tewari KS, Sill MW, Long HJ 3rd et al. Improved survival with bevacizumab in advanced
cervical cancer. N Engl J Med 2014; 370: 734–743.
30.Kitagawa R, Katsumata N, Shibata T et al. Paclitaxel plus carboplatin versus paclitaxel plus
cisplatin in metastatic or recurrent cervical cancer: the openlabel randomized phase III trial
JCOG0505. J Clin Oncol 2015; 33: 2129–2135
31. Andres Redondo, Nicoletta Colombo, Mary McCormack, Lydia Dreosti, et al., Primary results
from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and
paclitaxel for advanced cervical cancer, Gynecol Oncol., 2020 Oct;159(1):142-149.
32. https://interactiveguidelines.esmo.org/esmo-web-
app/toc/index.php?subjectAreaID=7&loadPdf=1
33.Tomoki Kimura, Toshiki Fujiwara, Tsubasa Kameoka, Yoshinori Adachi, Shinji Kariya,
Stereotactic body radiation therapy for metastatic lung metastases, Jpn J Radiol. 2022 Sep
13;40(10):995–1005.
34.Friedlander M, Grogan M; U.S. Preventative Services Task Force. Guidelines for the treatment
of recurrent and metastatic cervical cancer.Oncologist 2002; 7: 342–347.
